Search tips
Search criteria 


Logo of jrsocmedLink to Publisher's site
J R Soc Med. 1996 January; 89(1): 9–12.
PMCID: PMC1295634

The economics of cardiac failure.


Quality assurance and inclusion of prospective evaluation of costs of treatment in phase 3 and 4 pharmaceutical trials are becoming increasingly important. Not only high technology applications have to be investigated, but also relatively cheap but very common strategies for diagnostic work up and therapy. This may yield major savings. We are at the beginning of an era in which waste of resources may be reduced by scientific analysis with improvement in patient care and teaching achieved as a result.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (623K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Rodeheffer RJ, Jacobsen SJ, Gersh BJ, Kottke TE, McCann HA, Bailey KR, Ballard DJ. The incidence and prevalence of congestive heart failure in Rochester, Minnesota. Mayo Clin Proc. 1993 Dec;68(12):1143–1150. [PubMed]
  • Reitsma JB, Mosterd A, Koster RW, van Capelle FJ, Grobbee DE, Tijssen JG. Stijging van het aantal opnamen wegens hartfalen in Nederlandse ziekenhuizen in de periode 1980-1992. Ned Tijdschr Geneeskd. 1994 Apr 23;138(17):866–871. [PubMed]
  • Kleber FX, Niemöller L, Doering W. Impact of converting enzyme inhibition on progression of chronic heart failure: results of the Munich Mild Heart Failure Trial. Br Heart J. 1992 Apr;67(4):289–296. [PMC free article] [PubMed]
  • Muñoz E, Chalfin D, Birnbaum E, Mulloy K, Johnson H, Wise L. Hospital costs, resource characteristics, and the dynamics of death for patients with a primary diagnosis of congestive heart failure. N Y State J Med. 1989 Feb;89(2):60–63. [PubMed]
  • Seller RH, Lobley M. Efficient diagnosis of common complaints: a comparative study in the United States and England. J Fam Pract. 1991 Jul;33(1):41–46. [PubMed]
  • Kulick DL, Rahimtoola SH. Risk stratification in survivors of acute myocardial infarction: routine cardiac catheterization and angiography is a reasonable approach in most patients. Am Heart J. 1991 Feb;121(2 Pt 1):641–656. [PubMed]
  • Chapekis AT, Burek K, Topol EJ. The cost:benefit ratio of acute intervention for myocardial infarction: results of a prospective, matched pair analysis. Am Heart J. 1989 Nov;118(5 Pt 1):878–882. [PubMed]
  • Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol. 1993 Oct;22(4):955–962. [PubMed]
  • Jönsson B. Improving patient care: consequences for resource allocation. Cardiology. 1994;84(6):420–426. [PubMed]
  • Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991 Aug 1;325(5):303–310. [PubMed]
  • van Hout BA, Wielink G, Bonsel GJ, Rutten FF. Effects of ACE inhibitors on heart failure in The Netherlands: a pharmacoeconomic model. Pharmacoeconomics. 1993 May;3(5):387–397. [PubMed]
  • Tedder M, Anstadt MP, Wharton JM, Revishvili AS, Hegde SS, Lowe JE. Prophylactic implantable defibrillator patches in patients at high risk for malignant ventricular dysrhythmias. ASAIO J. 1992 Jul-Sep;38(3):M261–M265. [PubMed]
  • Loisance D, Benvenuti C, Lebrun T, Leclerc A, Tarral A, Sailly JC. Cost and cost effectiveness of the mechanical and pharmacologic bridge to transplantation. ASAIO Trans. 1991 Jul-Sep;37(3):M125–M127. [PubMed]
  • Poirier VL. Can our society afford mechanical hearts? ASAIO Trans. 1991 Oct-Dec;37(4):540–544. [PubMed]
  • Matzuk MM, Shlomchik M, Shaw LM. Making digoxin therapeutic drug monitoring more effective. Ther Drug Monit. 1991 May;13(3):215–219. [PubMed]
  • Schneider JK, Hornberger S, Booker J, Davis A, Kralicek R. A medication discharge planning program: measuring the effect on readmissions. Clin Nurs Res. 1993 Feb;2(1):41–53. [PubMed]
  • Goodwin DR. Critical pathways in home healthcare. J Nurs Adm. 1992 Feb;22(2):35–40. [PubMed]
  • Kane RL, Garrard J, Buchanan JL, Rosenfeld A, Skay C, McDermott S. Improving primary care in nursing homes. J Am Geriatr Soc. 1991 Apr;39(4):359–367. [PubMed]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press